跳到正文

医疗相关 ISO 标准准备与证据整理

按指定 ISO 标准组织差距、文件与证据准备,包含医疗器械相关体系资料,实际条文需要取得正式标准。

开源精选医疗业务35 个文件50,135 Stars浏览次数 0K-Dense-AI/scientific-agent-skills MIT版本 a1043ef
开始使用

适用环境:Python 3.11+; bundled CLIs use only the standard library and bounded local JSON/Markdown files, with no network access or credentials.

输入资料
指定标准与组织当前资料 获准使用的标准及证据范围 阅读本节完整说明
交付内容
准备与差距检查资料 证据清单和待完成事项 阅读本节完整说明
  1. 获取完整包,保留配套文件的目录结构。
  2. 按照原文准备所需工具、依赖与输入资料。
  3. 阅读对应使用步骤与输入输出说明,在自己的环境中验证结果。

使用提示摘自原文,配套文件保留来源版本;实际运行条件以各包说明为准。

正文

获取原文件

references/iso-14971.md

Research basis: 2026-10-01. This reference summarizes a preparation process and evidence architecture for medical device risk management. It does not reproduce requirements and is not a substitute for the standard.

ISO publications are copyrighted. Obtain ISO 14971 and ISO/TR 24971 from ISO, an ISO national member, or another authorized source; see ISO copyright. Do not ask an agent to retrieve, transcribe, summarize clause-by-clause, or store proprietary text.

Current edition, the guidance companion, and the European amendment

  • ISO 14971:2019 is Edition 3, published December 2019, reviewed and confirmed in 2025.
  • ISO/TR 24971:2020 is Edition 2 and is the guidance companion, following the same clause structure. It is a Technical Report: informative, not normative. Conformity is claimed to ISO 14971, never to ISO/TR 24971, and a TR cannot relax or reinterpret a normative requirement. Record which guidance the organization adopted and why. ISO marks the TR for revision; ISO/AWI TS 24971-1 is stage 20.00, under development. Keep the published 2020 TR as the guidance baseline until an authorized change review; a work item is not a published replacement.
  • EN ISO 14971:2019/A11:2021 is a European amendment to the EN adoption, cited for MDR and, through the corresponding decision, IVDR support. It does not change the international normative part. Track it only where the European source basis applies.

This profile supports risk evidence inside a named assurance lane

ISO 14971 is a device risk-management process standard. This skill does not define a standalone management-system certification scheme for it. Risk evidence supports other assessments, for example:

  • an ISO 13485 certification audit examines the risk-management process as part of the QMS;
  • an FDA inspection examines risk-based decisions against applicable FDA requirements;
  • an MDSAP audit treats risk management as a foundation across its process areas; and
  • EU conformity assessment examines the risk-management file as part of technical documentation against the applicable general safety and performance requirements.

If a third party supplies a certificate or assessment referencing ISO 14971, record its actual issuer, scheme, scope, and limitations. Do not treat its label as ISO 13485 certification, product approval, or a regulator decision. Report risk evidence as supporting the declared lane, without issuing an assurance result.

Hard boundary

This skill and its files cannot:

  • certify, approve, or validate a risk-management file or process;
  • determine device classification, intended use, reportability, conformity route, market access, or product authorization;
  • decide whether a risk is acceptable, whether benefit outweighs residual risk, or whether a risk-control measure is adequate or safe;
  • set or approve risk-acceptability criteria, severity or probability scales, or a risk matrix;
  • replace top management, the risk-management owner, qualified clinical and engineering reviewers, RA/QA, a notified body, or a regulator; or
  • infer that a hazard set is complete, or that residual risk is acceptable, from a template, a matrix, a document count, or a script result.

Use outputs as a list of evidence questions for accountable human review. Completeness of hazard identification cannot be established by any check in this skill — a zero-finding structural result says the declared links are present, not that the analysis found everything.

Process and evidence domains

The iso-14971 profile carries these domain labels for manifests and gap reports. They are workflow topics, not clause references:

risk-management-plan, risk-management-file, competence-and-authority, intended-use-and-characteristics, hazard-identification, risk-estimation-and-evaluation, risk-control-option-analysis, risk-control-implementation-and-verification, risk-control-side-effects-review, residual-risk-evaluation, benefit-risk-analysis, overall-residual-risk-evaluation, risk-management-review-and-report, production-and-postproduction-information, change-control.

Each domain needs an owner, status, evidence IDs, source/version reference, recorded approval, and links to open gaps.

The chain that has to hold together

Risk-management evidence is judged as a connected chain, not as a set of documents. For each analysed item, the following must be traceable in both directions:

intended use and reasonably foreseeable misuse → characteristics related to safety → hazard → foreseeable sequence of events → hazardous situation → harm with severity → probability basis → risk evaluation against declared criteria → risk-control option analysis and decision → implemented control → verification that the control was implemented → verification of its effectiveness → review for new or increased risks introduced by the control → residual risk evaluation → benefit-risk analysis where residual risk is not acceptable → contribution to overall residual risk → disclosure of residual risk → production and post-production information feeding back.

Break any one link and the file stops being evidence. The two links most often missing are verification of control effectiveness (distinct from verifying the control exists) and review of risks introduced by the control itself.

Build the traceability register with:

PYTHONDONTWRITEBYTECODE=1 python3 scripts/check_traceability.py \
  /path/to/traceability-matrix.json

That check links intended use, hazard or signal, risk evaluation, risk control, design input and output, verification, validation, production control, and post-market source. It verifies declared linkage, not analytical adequacy.

Where risk management meets the QMS

ISO 14971 work is not separable from the device QMS. Keep these joins explicit and evidenced:

  • Design and development — risk controls that are design outputs must appear as design inputs with verification, not only as risk-file rows.
  • Production — controls realized as process parameters, in-process checks, or acceptance criteria need production evidence, and process validation where the control cannot be fully verified on the finished device.
  • Purchasing — controls that depend on a supplier's process or component need supplier controls and change notification. See scripts/check_supplier_controls.py.
  • Post-market — complaints, service records, vigilance signals, and production nonconformities must actually re-enter risk estimation, with evidence that the file was reassessed and that changed estimates were acted on.
  • CAPA — where a risk estimate changes, the resulting action needs effectiveness evidence before closure. See scripts/check_capa.py.
  • Change control — any change to intended use, design, process, supplier, or materials triggers a documented risk reassessment.

The production and post-production feedback loop is the single most common structural gap: files that were complete at design transfer and never updated by field experience.

Risk-acceptability criteria and the matrix problem

Acceptability criteria belong in the risk-management plan, are set by authorized humans with a documented rationale, and must be applied consistently. Recurring failure modes to look for, none of which this skill can adjudicate:

  • criteria written after the analysis so that every risk lands acceptable;
  • probability values asserted with no stated basis and no data;
  • a matrix whose cells were adjusted per project to move results across the boundary;
  • risk reduction claimed from labelling or an instruction alone, where a design or protective measure was available;
  • residual risk described as acceptable with no benefit-risk analysis where the declared criteria were not met;
  • overall residual risk never evaluated as a whole — only item by item; and
  • no disclosure of residual risk to users where the analysis assumed it.

Flag these as blockers for authorized review. Do not resolve them.

Shared checks that apply here

  • scripts/validate_scope_intake.py --standard iso-14971 — declared scope, product families, intended use references, and applicability owners.
  • scripts/check_traceability.py — the risk/design/production/post-market chain.
  • scripts/check_capa.py — corrective action with effectiveness evidence.
  • scripts/check_supplier_controls.py — controls that depend on external providers.
  • scripts/validate_evidence_manifest.py and scripts/gap_analyzer.py with --standard iso-14971.

Sources

  • ISO 14971:2019 — catalogue entry
  • ISO/TR 24971:2020 — guidance companion
  • Decision (EU) 2022/757 — EN ISO 14971:2019/A11:2021 citation basis
  • references/iso-13485.md — the QMS lane this evidence usually supports
  • references/source-ledger.md — dated baseline and provenance limitations
  • references/assurance-lanes.md — the declared assurance purpose and limits

CONTACT HAONAN

联系haonan

医疗 AI · 产品与独立开发

刘浩南

关注医疗 AI 从 demo 到真实落地,聚焦产品化、商业化与院内工作流效率提升。

12年医疗产研经验,大湾区头部医疗AI公司前产品总监,独立开发者

医疗 AI 产品化医疗 AI 商业化院内工作流效率
刘浩南的微信联系二维码
微信扫一扫,联系 haonan